Filing Flows › Teva Pharmaceutical Industries (TEVA) › Q2 2026 › vs Q1 2026
Teva Pharmaceutical Industries (TEVA) Q2 2026 vs Q1 2026 (quarter over quarter)
Teva Pharmaceutical Industries's revenue rose $160M (+4%) from $4.0B in Q1 2026 to $4.1B in Q2 2026. The biggest changes: Product +$213M (+6%); Product and Service Other −$87.0M (-55%); Distribution Service +$37.0M (+9%).
Teva Pharmaceutical Industries, Q2 2026: revenue $4.1B (-0.8% year over year), operating margin -5.6%, net loss $575M, operating cash flow $411M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 7.4% | -5.2% | +12.6 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Product | $3.6B | $3.4B | $213M | +6% |
| Distribution Service | $433M | $396M | $37.0M | +9% |
| Product and Service Other | $70.0M | $157M | −$87.0M | -55% |
| License | $37.0M | $39.0M | −$2.0M | -5% |
| Revenue | $4.1B | $4.0B | $160M | +4% |
| Net loss | $575M | −$369M | $944M | — |
| Costs & expenses | $4.7B | $4.0B | $735M | +18% |
| Operating costs | $4.4B | $3.3B | $1.0B | +31% |
| Interest & other, net | $224M | $215M | $9.0M | +4% |
| Income tax | $121M | $67.0M | $54.0M | +81% |
| Cost of revenue | $2.0B | $2.0B | −$21.0M | -1% |
| Research & development | $970M | $222M | $748M | +337% |
| Sales & marketing | $717M | $696M | $21.0M | +3% |
| General & admin | $317M | $304M | $13.0M | +4% |
| Other operating costs | $380M | $98.0M | $282M | +288% |
| Operating cash sources | $986M | −$409M | $1.4B | — |
| Depreciation & amortization | $241M | $239M | $2.0M | +0.8% |
| Share-based compensation | $40.0M | $43.0M | −$3.0M | -7% |
| Working capital & other | $705M | −$691M | $1.4B | — |
| Net loss absorbed | $575M | −$369M | $944M | — |
| Operating cash flow | $411M | −$40.0M | $451M | — |
| Free cash flow (OCF − capex) | $307M | −$208M | $515M | — |
| Capital expenditures | $104M | $168M | −$64.0M | -38% |
Questions
How much did Teva Pharmaceutical Industries's revenue grow quarter over quarter in Q2 2026?
Teva Pharmaceutical Industries's revenue rose $160M (+4%) from $4.0B in Q1 2026 to $4.1B in Q2 2026.
What drove Teva Pharmaceutical Industries's revenue change in Q2 2026?
Product +$213M (+6%); Product and Service Other −$87.0M (-55%); Distribution Service +$37.0M (+9%).